Literature DB >> 1501000

Quantitation of transplanted hepatic mass necessary to cure the Gunn rat model of hyperbilirubinemia.

K Asonuma1, J C Gilbert, J E Stein, T Takeda, J P Vacanti.   

Abstract

The minimal hepatic mass necessary to reverse the metabolic defect of unconjugated hyperbilirubinemia in the rat model of Crigler-Najjar type I deficiency was determined using heterotopic (auxiliary) partial liver transplantation (HLT) and orthotopic liver transplantation (OLT). In HLT, the donor graft consisted of the right upper and/or right lower hepatic lobe(s) depending on the final mass of liver tissue desired for transplantation. The mass of the donor graft ranged from 12% to 23% of the whole organ (n = 12). The serum unconjugated bilirubin levels decreased quickly after HLT from a preoperative value of 8.98 +/- 0.34 mg/dL to 0.63 +/- 0.11 mg/dL in 24 hours, which was similar to OLT in which the levels decreased from a preoperative value of 8.20 +/- 0.44 mg/dL to 0.24 +/- 0.07 mg/dL in 24 hours. Conjugated bilirubin was excreted from the graft liver shortly after OLT and also from both the host and graft livers after HLT. This study demonstrates that using as little as 12% of the whole liver mass in HLT reduces serum bilirubin significantly in 24 hours in a fashion similar to whole-organ OLT. The clinical application of alternative therapies to whole-organ OLT such as HLT or hepatocyte transplantation may provide sufficient replacement therapy in metabolic disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501000     DOI: 10.1016/0022-3468(92)90850-7

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  15 in total

1.  Correction of congenital hyperbilirubinemia in homozygous Gunn rats by xenotransplantation of hamster livers.

Authors:  Yoshitaka Wakizaka; Toshio Miki; Abdul S Rao; Xue Wang; April L Goller; Anthony J Demetris; John J Fung; Thomas E Starzl; Luis A Valdivia
Journal:  Xenotransplantation       Date:  1997-11-01       Impact factor: 3.907

Review 2.  Engineered liver for transplantation.

Authors:  Basak E Uygun; Martin L Yarmush
Journal:  Curr Opin Biotechnol       Date:  2013-06-20       Impact factor: 9.740

3.  Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector.

Authors:  Gabriele Toietta; Viraj P Mane; Wilma S Norona; Milton J Finegold; Philip Ng; Antony F McDonagh; Arthur L Beaudet; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 4.  Concise Review: Organoids Are a Powerful Tool for the Study of Liver Disease and Personalized Treatment Design in Humans and Animals.

Authors:  Sathidpak Nantasanti; Alain de Bruin; Jan Rothuizen; Louis C Penning; Baukje A Schotanus
Journal:  Stem Cells Transl Med       Date:  2016-01-21       Impact factor: 6.940

Review 5.  Development of hepatic tissue engineering.

Authors:  Henning Cornelius Fiegel; Ulrich Kneser; Dietrich Kluth; Roman Metzger; Holger Till; Udo Rolle
Journal:  Pediatr Surg Int       Date:  2009-06-02       Impact factor: 1.827

Review 6.  Human hepatocyte transplantation for liver disease: current status and future perspectives.

Authors:  V Iansante; R R Mitry; C Filippi; E Fitzpatrick; A Dhawan
Journal:  Pediatr Res       Date:  2017-12-06       Impact factor: 3.756

Review 7.  Fetal and adult liver stem cells for liver regeneration and tissue engineering.

Authors:  H C Fiegel; Claudia Lange; U Kneser; W Lambrecht; A R Zander; X Rogiers; D Kluth
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

8.  Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome.

Authors:  Giulia Bortolussi; Lorena Zentillin; Jana Vaníkova; Luka Bockor; Cristina Bellarosa; Antonio Mancarella; Eleonora Vianello; Claudio Tiribelli; Mauro Giacca; Libor Vitek; Andrés F Muro
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

Review 9.  Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory.

Authors:  Henning C Fiegel; Peter M Kaufmann; Helge Bruns; Dietrich Kluth; Raymund E Horch; Joseph P Vacanti; Ulrich Kneser
Journal:  J Cell Mol Med       Date:  2007-11-16       Impact factor: 5.310

Review 10.  Treating inborn errors of liver metabolism with stem cells: current clinical development.

Authors:  Etienne Marc Sokal
Journal:  J Inherit Metab Dis       Date:  2014-03-26       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.